Physician profile
Timothy Hobbs
NPI 1366721318
$4,899.93
in general payments reported to CMS, 2019-2025
29 companies · $757 in 2025
The $757 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $96.75 · 2021: $510 · 2022: $883 · 2023: $1,165 · 2024: $805 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,629.37 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $713.22 | 2022-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $591.89 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $521.36 | 2022-2025 | Xiidra, Miebo, Infuse |
| Oyster Point Pharma, INC. | $411.65 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $340.83 | 2019-2025 | Rocklatan, Argos, Tryptyr |
| Abbvie INC. | $315.70 | 2022-2024 | |
| Biotissue Holdings INC. | $194.09 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $193.51 | 2019-2021 | |
| Dompe US, INC. | $189.84 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $187.02 | 2019-2023 | |
| Shire North American Group INC | $180.04 | 2019 | |
| Horizon Therapeutics Plc | $171.47 | 2021-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $163.98 | 2021-2022 | |
| Genentech USA, INC. | $144.90 | 2023 | Vabysmo |
| New World Medical,INC. | $110.76 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $99.68 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $67.21 | 2023 | Syfovre |
| Aerie Pharmaceuticals, INC. | $55.69 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $34.79 | 2019-2023 | Eylea |
| Ani Pharmaceuticals, INC. | $30.21 | 2025 | Iluvien |
| Glaukos Corporation | $29.10 | 2019-2024 | Idose |
| Allergan, INC. | $26.57 | 2021 | |
| Coherus Oncology, INC. | $21.28 | 2022 | |
| Alcon Research LLC | $20.75 | 2019 | |
| Amgen INC. | $19.88 | 2025 | Tepezza |
| Sight Sciences, INC. | $19.76 | 2021 | |
| Eyepoint US, INC. | $16.16 | 2019 | |
| Thea Pharma INC. | $15.74 | 2024 | Iyuzeh |
| Astellas Pharma US INC | $12.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hobbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.